August 01, 2014
2 min read
Save

Senate subcommittee examines new pricing policies for contact lenses

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The Senate Subcommittee on Antitrust Competition Policy and Consumer Rights held a hearing July 30 to explore contact lens pricing strategies initiated recently by contact lens manufacturers that would affect retail price competition, Sen. Amy Klobuchar (D-Minn.) said as she presided over the proceedings.

“This is intended as an exploratory hearing to give the subcommittee and regulators a better understanding of the reasons for the minimum pricing arrangements in this particular market,” Sen. Michael S. Lee (R-Utah) said at the hearing. “Price matters in this market. I’ve heard that as prices go up, consumers may wear their lenses longer than they should, potentially doing damage to their eyes in an attempt to save money.”

Since June 2013, Alcon, Bausch + Lomb and Johnson & Johnson Vision Care have announced new pricing policies whereby they will not provide certain contacts to any distributor if that distributor sells the product to consumers below certain minimum prices, R. Joe Zeidner, general counsel for 1-800 CONTACTS, testified as part of the panel. He said that such “resale price maintenance programs” harm contact lens customers by raising prices and limiting options for consumers to save money.

Millicent L. Knight, OD, CHC, FAARM, head of professional affairs for Johnson & Johnson, said at the hearing that the implementation of a unilateral pricing policy benefits patients by guaranteeing that any discounts are passed on to consumers. She said the new price for Acuvue products “is actually lower than the current national average selling price to consumers.”

The new strategy also replaces the “burdensome rebate process with instant savings,” and the “transparent pricing allows [consumers] to make the best purchasing decision based on quality, clinical need and price,” she said.

David A. Cockrell, OD, American Optometric Association president and a private practitioner, also testified, stressing that contact lenses are a medical device with potential serious health consequences if used unsupervised or without a prescription. He said patients today have more choices for a broader range of vision correction needs, and today’s lenses are much safer, better quality and competitively priced.

Cockrell said the four doctors in his practice use contact lenses from 10 to 15 different manufacturers, each with multiple types and parameters.

George Slover, senior policy counsel for Consumers Union, also a panel member, stated: “Whether the new practice constitutes an antitrust violation from a legal standpoint, from a practical standpoint it is anticompetitive to refuse to allow discounting.

“There’s no reason for the provision of professional eye care services to be tied to the sale of contact lenses,” he continued. “But the new unilateral pricing restrictions stand to result in much the same tying effect. Consumers will still have the right to shop around, but they will no longer be able to save money by doing so.”